Jamie Denison-Pender founded Prescient in 2007, as a subsidiary of BRG Ltd., and was CEO until the end of 2022. Under his leadership Prescient grew to become a leading biopharma product and portfolio strategy firm with ~450 employees in offices across the US, Europe and Asia. He successfully led the business through an MBO, two PE events and a tuck in acquisition. By the time he stood down as CEO at the end of 2022, Prescient were partnering with almost 70 biopharma organizations, more than 250 assets and brands and functional leaders across CI, medical affairs, clinical development, early commercial, global marketing and market research. The business grew every year and had delivered >20 quarters of consecutive growth under PE ownership at the end of FY22. Baird Capital held Prescient for three and a half years before selling to Bridgepoint Development Capital in 2021.In H2 2023, following a minority investment from Baird Capital, Jamie became a NED at JMAN Group. Here he supports the founders and management team to execute on their path-to-value, access new markets, increase their geographical footprint and scale their infrastructure.
Listed skills include Biotechnology, Pharmaceutics, Lifesciences, Competitive Analysis, and 33 others.
